FDA Approves Fremanezumab-vfrm for Pediatric Migraine Prevention, Marking a First for CGRP Antagonists

The FDA has granted a significant expanded approval for fremanezumab-vfrm (Ajovy), a calcitonin gene-related peptide (CGRP) antagonist developed by Teva Pharmaceuticals. The drug is now indicated for the preventive treatment of episodic migraine in a new patient population: children and adolescents aged 6 to 17 years who weigh 45 kg or more. This approval is a landmark, as fremanezumab is the first CGRP antagonist to be approved for pediatric patients, addressing a major gap in care for a condition that is often underdiagnosed and undertreated in this age group.

Clinical Evidence from the SPACE Trial

The expanded indication is based on the positive outcomes of the Phase 3, multicenter, randomized, double-blind, placebo-controlled SPACE trial (NCT04458857). This study was specifically designed to evaluate the efficacy, safety, and tolerability of fremanezumab in a pediatric population with episodic migraine.

Primary Endpoint Met: The trial’s primary endpoint, which measured the mean change from baseline in the monthly average of migraine days over a 3-month period, was successfully met. Fremanezumab-treated patients experienced a statistically significant reduction of 2.5 monthly migraine days compared to a reduction of 1.4 days in the placebo group (P = .0210).
Rapid Onset of Action: The therapeutic effects were observed as early as one month after treatment initiation.
High Response Rate: A notable 47.2% of patients on fremanezumab achieved at least a 50% reduction in monthly migraine days, compared to only 27.0% of patients on placebo (P = .0016).
Reduced Acute Medication Use: Fremanezumab also led to a significant reduction in the use of acute migraine medication, demonstrating its effectiveness in lessening the overall burden of the condition.
Consistent Across Subgroups: The benefits of the treatment were found to be similar across different age groups (6-11 years and 12-17 years) and genders.

Safety and Administration

The safety profile of fremanezumab in the pediatric trial was similar to that observed in adults. The rates of treatment-emergent adverse events (AEs) were comparable between the fremanezumab and placebo groups (55% vs. 49%, respectively). No deaths or treatment discontinuations were attributed to the drug.

Fremanezumab is available in a 225 mg/1.5 mL single-dose injection, which can be administered once a month. This convenient, at-home administration option is expected to improve treatment adherence and reduce the burden on both patients and their families. This expanded approval offers a crucial, targeted treatment option for clinicians managing a condition that can severely impact a child’s school performance, social life, and overall well-being.